Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Jonathan W. Friedberg, Julie M. Vose, Jennifer L. Kelly, Faith Young, Steven H. Bernstein, Derick Peterson, Lynn Rich, Susan Blumel, Nicole K. Proia, Jane Liesveld, Richard I. Fisher, James O. Armitage, Steven Grant, John P. Leonard

Blood (2011) 117 (10): 2807–2812.

https://doi.org/10.1182/blood-2010-11-314708

Published: 2011

Journal Articles

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Andrei Shustov, MD, Barbara Pro, MD, Christian Gisselbrecht, MD, Leslie Popplewell, M.D., Nancy L. Bartlett, MD, Mary Jo Lechowicz, MD, Jasmine M. Zain, MD, Faith Young, Richard R. Furman, MD, Steven M. Fruchtman, MD, Steven M Horwitz, MD, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 4882.

https://doi.org/10.1182/blood.V116.21.4882.4882

Published: 2010

Journal Articles

Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens

Andre Goy, MD, Barbara Pro, MD, Kerry Joanne Savage, MD, BSc, MSc, Nancy L. Bartlett, MD, Mary Jo Lechowicz, MD, Eric D Jacobsen, MD, Faith Young, Michael Crump, MD, FRCPC, Hossein Borghaei, DO, Brian Link, Steven M. Fruchtman, MD, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 1753.

https://doi.org/10.1182/blood.V116.21.1753.1753

Published: 2010

Journal Articles

Blood CD34 Levels as a Predictor of Successful Peripheral Blood Stem Cell Mobilization In Consecutive Autologous Stem Cell Apheresis Patients From a Single Transplant Center

Sujatha Mogili, Rui Chen, Michael Becker, Faith Young, Gordon L. Phillips, II, MD, Sue Frauenhofer, Donna Cimbalo, Sean Czaja, Diane Nichols, Jane L. Liesveld, MD

Blood (2010) 116 (21): 4440.

https://doi.org/10.1182/blood.V116.21.4440.4440

Published: 2010

Journal Articles

High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era

Makiko Ban-Hoefen, MD, Jonathan W. Friedberg, MD, Jennifer L. Kelly, PhD, MPH, Steven H. Bernstein, MD, Jane L. Liesveld, MD, Faith Young, MD, Richard I Fisher, MD, Louis Constine, MD, Michael Becker, MD, Gordon L. Phillips, II, MD

Blood (2010) 116 (21): 2393.

https://doi.org/10.1182/blood.V116.21.2393.2393

Published: 2010

Journal Articles

Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial.

Jonathan W. Friedberg, MD, Julie M. Vose, M.D., Jennifer L Kelly, PhDMPH, Faith Young, MD, Jane Liesveld, MD, James O. Armitage, M.D., Nicole Proia, MPH, Kim Cruttenden, N.P., John P. Leonard, MD

Blood (2009) 114 (22): 924.

https://doi.org/10.1182/blood.V114.22.924.924

Published: 2009

Journal Articles

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab

Shannon P. Hilchey, Ollivier Hyrien, Tim R. Mosmann, Alexandra M. Livingstone, Jonathan W. Friedberg, Faith Young, Richard I. Fisher, Raymond J. Kelleher, Jr, Richard B. Bankert, Steven H. Bernstein

Blood (2009) 113 (16): 3809–3812.

https://doi.org/10.1182/blood-2008-10-185280

Published: 2009

Journal Articles

Effect of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy in Patients (pts) with Non Hodgkin’s Lymphoma (NHL): Analysis of SWOG Clinical Trials.

Julia Schaefer-Cutillo, Vaseem Chengazi, Derick R Peterson, David G. Maloney, Kevin Kibler, Erin Cebula, Steven Bernstein, Faith Young, Oliver W. Press, Lisa M. Rimsza, Richard I. Fisher, Jonathan W. Friedberg, MD

Blood (2008) 112 (11): 2000.

https://doi.org/10.1182/blood.V112.11.2000.2000

Published: 2008

Journal Articles

Support for a Possible "Vaccinal" Effect of Rituximab; Lymphoma Idiotype Specific T-Cell Responses in Follicular Lymphoma Patients Treated with Rituximab.

Shannon P. Hilchey, Ollivier Hyrien, Richard Bankert, Daniel P. Gold, Faith Young, Jonathan Friedberg, Richard I. Fisher, Steven H. Bernstein

Blood (2007) 110 (11): 3424.

https://doi.org/10.1182/blood.V110.11.3424.3424

Published: 2007

Journal Articles

Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?.

Manzurul A. Sikder, MD, Sughosh Dhakal, Jennifer Kelly, MPH, Steven H. Bernstein, MD, Faith Young, MD, Richard I. Fisher, MD, Jonathan Friedberg, MD, Louis Constine, MD

Blood (2007) 110 (11): 3433.

https://doi.org/10.1182/blood.V110.11.3433.3433

Published: 2007

Journal Articles

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Camille N. Abboud, MD, Alison Walker, MD, Rami S. Komrokji, MD, Jainulabdeen J. Ifthikharuddin, MD, Connie Sparks, BS,CRA, Kelly Likly, MSN, Patti Messina, BSN, Deborah Mulford, MD, Jonathan Friedberg, MD, Michael W. Becker, MD, Faith Young, MD, Steven H. Bernstein, MD, August J. Salvado, MD, Gordon L. Phillips, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 1958.

https://doi.org/10.1182/blood.V108.11.1958.1958

Published: 2006

Journal Articles

Pre-B Cell Acute Lymphoblastic Leukemia Cells Carrying a Bcr/Abl Translocation Retain Sensitivity to Minor Histocompatibility Antigen Specific T Cells but Are Resistant to Natural Killer Cells: Implications for Manipulation of Graft Versus Leukemia Effects.

Craig A. Mullen, MD, PhD, Andrew Campbell, MS, Faith Young, MD, Craig T. Jordan, PhD

Blood (2006) 108 (11): 3247.

https://doi.org/10.1182/blood.V108.11.3247.3247

Published: 2006

Journal Articles

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

Gordon L. Phillips, MD, Camille N. Abboud, MD, Steven H. Bernstein, MD, Jonathan W. Friedberg, MD, Michael W. Becker, MD, Jainulabdeen J. Ifthikharuddin, MD, Faith Young, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 3076.

https://doi.org/10.1182/blood.V108.11.3076.3076

Published: 2006

NARROW

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens

Blood CD34 Levels as a Predictor of Successful Peripheral Blood Stem Cell Mobilization In Consecutive Autologous Stem Cell Apheresis Patients From a Single Transplant Center

High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era

Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial.

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab

Effect of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy in Patients (pts) with Non Hodgkin’s Lymphoma (NHL): Analysis of SWOG Clinical Trials.

Support for a Possible "Vaccinal" Effect of Rituximab; Lymphoma Idiotype Specific T-Cell Responses in Follicular Lymphoma Patients Treated with Rituximab.

Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?.

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Pre-B Cell Acute Lymphoblastic Leukemia Cells Carrying a Bcr/Abl Translocation Retain Sensitivity to Minor Histocompatibility Antigen Specific T Cells but Are Resistant to Natural Killer Cells: Implications for Manipulation of Graft Versus Leukemia Effects.

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only